ASX-LISTED cannabis and nano-delivery system company Medlab has released progress results on its product development, including the successful completion of stage 1 of its Nanabis cancer trial at Sydney's Royal North Shore Hospital.
Formal approval has been received from the Independent Data Safety Monitoring Board to proceed to Stage 2 of the trial, focusing again on safety alongside dosage escalation and tolerance.
Other developments include Medlab's NanaBidialanti-emetic treatment which is about to commence a clinical trial for patients with chemotherapy-induced nausea, while a third announcement related to a trial of NanoStat, a nano-particle spray of a statin.
Called NanoCelle, the system enables delivery of small doses and with the trial now completed, results will be available in a month.
The company is also undertaking international negotiations to enhance global market penetration.
The above article was sent to subscribers in Pharmacy Daily's issue from 31 Oct 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 31 Oct 18
